Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2018195593) CULTURING METHOD FOR CYSTIC FIBROSIS CELLS AND SCREENING METHOD BASED THEREON AND TREATMENT OF CYSTIC FIBROSIS
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2018/195593 International Application No.: PCT/AU2018/050373
Publication Date: 01.11.2018 International Filing Date: 24.04.2018
IPC:
C12N 5/071 (2010.01) ,C12N 5/10 (2006.01) ,C12N 15/63 (2006.01)
C CHEMISTRY; METALLURGY
12
BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
N
MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
5
Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
07
Animal cells or tissues
071
Vertebrate cells or tissues, e.g. human cells or tissues
C CHEMISTRY; METALLURGY
12
BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
N
MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
5
Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
10
Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
C CHEMISTRY; METALLURGY
12
BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
N
MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15
Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09
Recombinant DNA-technology
63
Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
Applicants:
TELETHON KIDS INSTITUTE [AU/AU]; 100 Roberts Road Subiaco, Western Australia 6008, AU
Inventors:
GARRATT, Luke Wisely; AU
KICIC, Anthony; AU
TREND, Stephanie; AU
Agent:
GRIFFITH HACK; Level 22 Allendale Square, 77 St Georges Terrace Perth, Western Australia 6000, AU
Priority Data:
201790149124.04.2017AU
Title (EN) CULTURING METHOD FOR CYSTIC FIBROSIS CELLS AND SCREENING METHOD BASED THEREON AND TREATMENT OF CYSTIC FIBROSIS
(FR) PROCÉDÉ DE CULTURE DE CELLULES DE FIBROSE KYSTIQUE ET PROCÉDÉ DE CRIBLAGE BASÉ SUR CE DERNIER ET TRAITEMENT DE LA FIBROSE KYSTIQUE
Abstract:
(EN) The present invention relates to methods for screening cystic fibrosis patient cells to identify suitable therapeutic agents for the treatment of cystic fibrosis and/or the bacterial infections associated with cystic fibrosis. In particular, the present invention relates to a method of culturing cells from a cystic fibrosis patient comprising: (i) providing primary airway epithelial cells (pAEC) from said cystic fibrosis patient; and (ii) co-culturing said pAEC with an irradiated fibroblast feeder cell in the presence of tissue culture medium and at least one Rho-associated kinase (ROCK) inhibitor to expand the number of pAEC in culture. In addition, the invention relates to an expression construct comprising a nucleic sequence encoding a reporter polypeptide operatively linked to a nucleic acid sequence encoding CFTR or a mutant thereof, which facilitates expression of 150,000 copies of the CFTR or mutant CFTR polypeptide on the cytoplasmic membrane of a cell.
(FR) La présente invention concerne des procédés de criblage de cellules de patient atteint de fibrose kystique pour identifier des agents thérapeutiques convenant au traitement de la fibrose kystique et/ou des infections bactériennes associées à la fibrose kystique. En particulier, la présente invention concerne un procédé de culture de cellules provenant d’un patient atteint de fibrose kystique comprenant : (i) la préparation de cellules épithéliales des voies aériennes primaires (pAEC) provenant dudit patient atteint de fibrose kystique ; et (ii) la co-culture desdites pAEC avec une cellule nourricière de fibroblaste exposée à un rayonnement en présence d’un milieu de culture tissulaire et d’au moins un inhibiteur de kinase associé à Rho (ROCK) pour accroître le nombre de pAEC dans la culture. De plus, l’invention concerne une construction d’expression comprenant une séquence nucléique codant pour un polypeptide rapporteur fonctionnellement lié à une séquence d’acides nucléiques codant pour CFTR ou son mutant, qui facilite l’expression de 150 000 copies du CFTR ou du polypeptide CFTR mutant sur la membrane cytoplasmique d’une cellule.
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)